Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Martin

Allergy & Immunology Wynnewood, PA Medical Doctor

NPI 1225051337 CMS profile 327991

100 E Lancaster Ave, Lankenau Medical Building Suite 237 West, Wynnewood, PA 19096

Open in the dashboard

General payments

$11,926

488 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, George Martin of Wynnewood, PA is reported in the CMS Open Payments database as having received $11,926 across 488 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,303 101
2024 General $1,845 83
2023 General $1,178 60
2022 General $1,527 77
2021 General $1,178 71
2020 General $589 31
2019 General $1,307 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Martin
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to George Martin were reported at $4,303. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year George Martin Allergy & Immunology median Middle half National median
2019 $1,307 $594 $163–$1,512 $163
2020 $589 $426 $106–$1,233 $114
2021 $1,178 $638 $157–$1,708 $132
2022 $1,527 $790 $205–$1,961 $149
2023 $1,178 $852 $220–$2,147 $160
2024 $1,845 $865 $203–$2,267 $164
2025 $4,303 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sanofi US Services Inc. $2,335 1 payment
  2. GlaxoSmithKline, LLC. $1,380 74 payments
  3. Regeneron Healthcare Solutions, Inc. $1,372 74 payments
  4. AstraZeneca Pharmaceuticals LP $1,190 51 payments
  5. Amgen Inc. $831 48 payments
  6. Genzyme Corporation $708 29 payments
  7. kaleo, Inc. $392 21 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $386 17 payments
  9. Kowa Pharmaceuticals America, Inc. $375 29 payments
  10. AbbVie, Inc. $349 19 payments
  11. Other $2,607 125 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,502 484 payments
  2. Consulting Fee $2,335 1 payment
  3. Education $89 3 payments
Products named General payments · program years 2019–2025
  1. AYVAKIT $2,335 1 payment
  2. DUPIXENT Inflammation And Immunology $1,101 57 payments
  3. DUPIXENT Immunology $1,090 44 payments
  4. NUCALA $723 40 payments
  5. Repatha $594 33 payments
  6. TRELEGY ELLIPTA $486 23 payments
  7. Otezla $470 29 payments
  8. AUVI-Q $363 19 payments
  9. Livalo $325 26 payments
  10. UBRELVY $304 17 payments
  11. Other $6,035 311 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 120 drugs

Part D claims

6,155

Median for Allergy/ Immunology: 449

Drug cost

$1,027,263

Median for Allergy/ Immunology: $169,700

Branded share of claims

30.1%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 118 $154,058
Symbicort Budesonide/Formoterol Fumarate Brand 284 $124,480
Nucala Mepolizumab Brand 22 $75,481
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 247 $65,164
Eliquis Apixaban Brand 58 $59,947
Repatha Sureclick Evolocumab Brand 58 $56,465
Dupixent Pen Dupilumab Brand 14 $54,508
Ozempic Semaglutide Brand 52 $53,021
Januvia Sitagliptin Phosphate Brand 36 $49,229
Qvar Redihaler Beclomethasone Dipropionate Brand 66 $39,888

The 10 drugs with the highest cost, of 120 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$475,623

Of which drugs: $69,958

Medicare patients

366

Average age 75

Services billed

23,230

235 women, 131 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 51%
Ischemic heart disease 39%
Diabetes 32%
Osteoporosis 26%
Cancer 20%
Chronic kidney disease 19%
Depression 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 Office 43 43 $5,624
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 170 172 $3,684
Injection, methylprednisolone acetate, 80 mg J1040 Office 17 52 $377
Injection, methylprednisolone acetate, 1 mg J1010 Office 46 147 $15

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $275
  • GENZYME CORPORATION $237
$512 14 —
Xembify
  • Grifols USA, LLC $119
$119 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $117
$117 — —
EOHILIA
  • Takeda Pharmaceuticals U.S.A., Inc. $76
$76 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $76
$76 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

488 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record